ArticleCancers2020
Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study.
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- From Physiology to Clinical Practice in Pancreatic Cancer-Related Thromboembolism-A Review.Cancers · 2026Review
- Association between modifications in intravenous chemotherapy dose and disease-free survival and related influencing factors in lung cancer patients: a retrospective study based on inverse probability weighting.Cancer chemotherapy and pharmacology · 2026Article
- Arterial and venous thromboembolic events in patients with cancer treated with targeted therapies: a population-based cohort study.EClinicalMedicine · 2025Article
- Biological Activity Evaluation of Phenolic Isatin-3-Hydrazones Containing a Quaternary Ammonium Center of Various Structures.International journal of molecular sciences · 2024Article
- Base-Catalyzed Reaction of Isatins and (3-Hydroxyprop-1-yn-1-yl)phosphonates as a Tool for the Synthesis of Spiro-1,3-dioxolane Oxindoles with Anticancer and Anti-Platelet Properties.Molecules (Basel, Switzerland) · 2024Article
- Review
- Deep Vein Thrombosis as a Complication of Gemcitabine-Capecitabine Chemotherapy in Adenocarcinoma of Gallbladder.Journal of blood medicine · 2024Article
- Venous Thromboembolism and Primary Thromboprophylaxis in Perioperative Pancreatic Cancer Care.Cancers · 2023Review
- Antithrombin Deficiency and Thrombosis: A Wide Clinical Scenario Reported in a Single Institution.Journal of blood medicine · 2023Article
- Hemostasis and cancer: Impact of haemostatic biomarkers for the prediction of clinical outcomes in patients with cancer.Journal of thrombosis and haemostasis : JTH · 2022Review
- Evaluation of the Khorana, PROTECHT, and 5-SNP scores for prediction of venous thromboembolism in patients with cancer.Journal of thrombosis and haemostasis : JTH · 2021Article
- Tissue factor and its procoagulant activity on cancer-associated thromboembolism in pancreatic cancer.Cancer science · 2021Article
- Cancer Therapy-Associated Thrombosis.Arteriosclerosis, thrombosis, and vascular biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 4 countries.
Funding
Abstract
Gemcitabine and platinum-based agents could increase the risk of venous thromboembolism (VTE) in patients with cancer. We evaluated the additive predictive utility of these agents towards cancer-associated VTE beyond a recently developed and externally validated clinical prediction model, which was based on tumor entity and continuous D-dimer levels. Analysis was performed in the derivation cohort of this model, obtained from the Vienna Cancer and Thrombosis Study (CATS), a prospective observational cohort study (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.